Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Antibodies:
anti-Mouse (Murine) Antibodies:
Go to our pre-filtered search.
Human Polyclonal Lp-PLA2 Primary Antibody for IF (p), IHC (p) - ABIN686722
Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. in Atherosclerosis 2013
Show all 2 Pubmed References
Human Polyclonal Lp-PLA2 Primary Antibody for ELISA, WB - ABIN4238414
Moldoveanu, Serban, Marta, Serban, Huica: Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2011
Human Monoclonal Lp-PLA2 Primary Antibody for ELISA - ABIN563501
Klee, Finlay, McDonald, Attewell, Hebrink, Dyer, Love, Vasmatzis, Li, Beechem, Klee: Bioinformatics methods for prioritizing serum biomarker candidates. in Clinical chemistry 2007
Human Polyclonal Lp-PLA2 Primary Antibody for FACS, IHC (p) - ABIN653776
Bouchareb, Mahmut, Nsaibia, Boulanger, Dahou, Lépine, Laflamme, Hadji, Couture, Trahan, Pagé, Bossé, Pibarot, Scipione, Romagnuolo, Koschinsky, Arseneault, Marette, Mathieu: Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. in Circulation 2015
The substitution of whole grains and legumes for refined rice resulted in a reduction in Lp-PLA2 activities in plasma and PBMCs partly through improved glycemic control, increased consumption of protein relative to carbohydrate, and reduced lipid peroxides.
High levels of high-sensitive C-reactive protein (show CRP Antibodies) and lipoprotein-associated phospholipase-A2 did not relate to endothelial dysfunction in ST-elevation myocardial infarction patients treated with percutaneous coronary intervention.
In persistent prehypertension, increased ox-LDL hydrolysis by Lp-PLA2 enhances arterial stiffness without an age-related increase in blood pressure.
Data show that all the six inflammation-related CpG-SNPs genotypes including IL1B (show IL1B Antibodies) rs16944, IL1R2 (show IL1R2 Antibodies) rs2071008, PLA2G7 rs9395208, FAM5C rs12732361, CD40 (show CD40 Antibodies) rs1800686, and CD36 (show CD36 Antibodies) rs2065666 were associated with coronary heart disease (CHD (show CHDH Antibodies)), suggesting an important role of inflammation in the risk of CHD (show CHDH Antibodies).
LpPLA2 is found in both LDL and HDL (show HSD11B1 Antibodies) and is distributed differently in men with T1D without any relationship to CAC (show CA2 Antibodies) score progression
In a multi-ethnic cohort without baseline cardiovascular disease, higher Lp-PLA2 mass and activity were not significantly associated with an increased risk for incident peripheral arterial disease.
The simultaneous presence of the PLA2G7 279VV genotype and persistence of overweight synergistically increases the risk for hypertension.
Elevated mass and activity of Lp-PLA2 related to inflammation and atherosclerosis may take part in the development of kidney injury and atherosclerosis in patients with chronic kidney disease.
Taken together, these results revealed that Lp-PLA2 silencing protected against ox-LDL-induced oxidative stress and cell apoptosis via Akt (show AKT1 Antibodies)/mTOR (show FRAP1 Antibodies) signaling pathway in human THP1 (show GLI2 Antibodies) macrophages.
Plasma Lp-PLA2 concentration was independently associated with coronary heart disease in Chinese patients.
Lp-PLA2 augments the inflammatory response after MI and antagonizes healing by disrupting the balance between inflammation and repair.
Plg (show PLG Antibodies) from mouse plasma contains oxPtdPC adducts that are not affected by the action of Lp-PLA(2), suggesting that linkage to Plg (show PLG Antibodies) protects oxPtdPCs from metabolism during their transport in the plasma.
SAA (show SAA1 Antibodies) up-regulates Lp-PLA2 production significantly via a FPRL1 (show FPR2 Antibodies)/MAPKs./PPAR-gamma (show PPARG Antibodies) signaling pathway.
Deletion of Pla2g7 decreases small intestinal polyp and colon tumor incidence in ApcMin/+ mice.
Macrophage VLDL receptor (show VLDLR Antibodies) promotes PAFAH (show PAFAH1B1 Antibodies) secretion in mother's milk and suppresses systemic inflammation in nursing neonates.
Pla2g7 and Tnfrsf21 (show TNFRSF21 Antibodies) have been identified as genetic susceptibility to influenza genes in mice.
Pla2g7 plays a crucial physiological role in smooth muscle cell differentiation from stem cells, and interactions between Nrf3 (show NFE2L3 Antibodies) and Pla2g7 are essential.
The effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE (show APOE Antibodies)-deficient mice and its associated mechanisms, are reported.
Studies designed to evaluate the ability of precursor forms of PAF-AH to mature to fully active proteins indicated that the N-terminal end of human and mouse PAF-AH played important and opposite roles in this process.
PAF acetylhydrolase activity in the uterus in early pregnancy was not produced locally but probably resulted from the influx of the plasma form of the enzyme
The results demonstrated that Lp-PLA2 is associated with triglycerides which may be helpful for understanding the relationship of this protein with cardiovascular disease.
Effect of splenectomy and autologous spleen transplantation on the serum PAF-AH activity and acute-phase response in a porcine model are reported.
observations support a proatherogenic role for Lp-PLA2
Variable gene expression (eg, matrix metalloproteinase-9 (show MMP9 Antibodies), CCL2 (show CCL2 Antibodies) and Lp-PLA(2) mRNAs), both in regard to the arterial bed and duration of disease, was associated with variable plaque development and progression.
The significant correlation between PLA2G7 RNA expression in plaque macrophages and plasma PAFAH activity suggests that the latter is a consequence, rather than a cause of macrophage accumulation.
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.
, 2-acetyl-1-alkylglycerophosphocholine esterase
, LDL-associated phospholipase A2
, PAF 2-acylhydrolase
, PAF acetylhydrolase
, group-VIIA phospholipase A2
, lipoprotein-associated phospholipase A2
, platelet-activating factor acetylhydrolase
, group VII phospholipase A2
, plasma PAF acetylhydrolase